Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status

摘要: Abstract Background The aim of this study was to evaluate the effect cetuximab on health-related quality life (HRQoL) in NORDIC-VII trial metastatic colorectal cancer (mCRC), and assess HRQoL relation RAS BRAF mutation status inflammatory biomarkers. Patient methods assessed using European Organisation for Research Treatment Cancer Quality Life Questionnaire Core 30 (QLQ-C30) at baseline, after every fourth cycle chemotherapy, end treatment. during 12 cycles chemotherapy evaluated over time, compared between treatment arms, association with tumour markers. Results QLQ-C30 completed by 512 patients (90%) before start variables were well balanced across arms no statistically significant differences seen. Patients -mutated tumours reported poorer baseline subsequent time points than or / wild-type tumours. high serum interleukin-6 (IL-6) C-reactive protein (CRP) had markedly impaired normal levels. There a reduction IL-6 CRP levels improvement from 4. Conclusion addition did not affect mCRC patients. have both worse prognosis poor HRQoL. associations systemic markers reduced suggest that might benefit anti-inflammatory